Treatments in Endocrinology

, Volume 3, Issue 2, pp 91–103

Hypoglycemia in Type 1 Diabetes Mellitus

Pathophysiology and Prevention
Review Article


Spontaneous hypoglycemia is uncommon in the general (nondiabetic) population, but iatrogenic hypoglycemia is rife in patients with type 1 diabetes mellitus, among whom hypoglycemia constitutes a barrier to optimal glycemic control. The obligate dependence on exogenous insulin, together with the current imperfection in insulin therapies, generates degrees of blood glucose fluctuations that often exceed physiological boundaries in these patients. Downward swings in blood glucose levels, if sustained, result in hypoglycemia and significant morbidity and mortality. Hypoglycemia in type 1 diabetes indicates an imbalance between caloric supply and glucose use in response to insulin or exercise. Counterregulatory mechanisms that auto-correct iatrogenic hypoglycemia often become progressively impaired in these patients. This defective counterregulation, together with the imperfections in insulin delivery, set the stage for significant morbidity from iatrogenic hypoglycemia. Recurrent episodes of iatrogenic hypoglycemia induce a state of hypoglycemia unawareness and defective counterregulation, which defines the syndrome of hypoglycemia-associated autonomic failure (HAAF). The reduced awareness of, and counterregulatory responses to, hypoglycemia in patients with HAAF lead to worsening episodes of severe hypoglycemia.

Approaches to the prevention of hypoglycemia include glucose monitoring, patient education, meal planning, and medication adjustment. In patients with HAAF, scrupulous avoidance of iatrogenic hypoglycemia may restore the symptomatic and counterregulatory responses to hypoglycemia. Behavioral training focusing on recognition of the more subtle symptoms and signs of evolving hypoglycemia may be beneficial to some patients with HAAF. A methodical search for the pattern and etiology of iatrogenic hypoglycemia is a prerequisite for the identification of the best preventive approach. With proper education, patients with type 1 diabetes and their physicians can learn to prevent or minimize the risk of hypoglycemia while pursuing excellence in glycemic control.


  1. 1.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86CrossRefGoogle Scholar
  2. 2.
    Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103–17PubMedCrossRefGoogle Scholar
  3. 3.
    The United Kingdom Prospective Diabetes Study Research Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837–53CrossRefGoogle Scholar
  4. 4.
    The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968–83CrossRefGoogle Scholar
  5. 5.
    Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–12PubMedCrossRefGoogle Scholar
  6. 6.
    Khaw K-T, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001; 322: 1–6CrossRefGoogle Scholar
  7. 7.
    Cryer PE. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 1994; 43: 1378–89PubMedCrossRefGoogle Scholar
  8. 8.
    Cryer PE. Hypoglycemia: pathophysiology, diagnosis and treatment. New York: Oxford University Press, 1997Google Scholar
  9. 9.
    MacLeod KM, Hepburn DA, Frier BM. Frequency and morbidity of severe hypoglycemia in insulin-treated diabetic patients. Diabet Med 1993; 10: 238–45PubMedCrossRefGoogle Scholar
  10. 10.
    Reichard P, Berglund B, Britz A, et al. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 1991; 230: 101–8PubMedCrossRefGoogle Scholar
  11. 11.
    Abaira C, Colwell JA, Nuttall FQ, et al. Veterans affairs cooperative study on glycémic control and complications in type II diabetes: results of the feasibility trial. Diabetes Care 1995; 18: 1113–23CrossRefGoogle Scholar
  12. 12.
    Hepburn DA, MacLeod KM, Pell ACH, et al. Frequency and symptoms of hypoglycemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med 1993; 10: 231–7PubMedCrossRefGoogle Scholar
  13. 13.
    Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26: 1902–12PubMedCrossRefGoogle Scholar
  14. 14.
    The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271–86CrossRefGoogle Scholar
  15. 15.
    Kaufman FR, Austin J, Neinstein A, et al. Nocturnal hypoglycemia detected with the continuous glucose monitoring system in pediatrie patients with type 1 diabetes. J Pediatr 2002; 141: 625–30PubMedCrossRefGoogle Scholar
  16. 16.
    Due to fear of fatal hypoglycemia, parents tolerate dangerous blood glucose values [in German]. MMW Fortschr Med 2002; Apr 4; 144 (14): 53Google Scholar
  17. 17.
    Ramsey S, Summers KH, Leong SA, et al. Productivity and medical costs of diabetes in a large employer population. Diabetes Care 2002; 25: 23–9PubMedCrossRefGoogle Scholar
  18. 18.
    The Diabetes Control and Complications Trial Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 1991; 90: 450–9Google Scholar
  19. 19.
    Miihlhauser I, Overmann H, Bender R, et al. Risk factors for severe hypoglycaemia in adult patients with type 1 diabetes: a prospective population based study. Diabetologia 1997; 41: 1274–82Google Scholar
  20. 20.
    Allen C, LeCaire T, Palta M, et al. Risk factors for frequent and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001; 24: 1878–81PubMedCrossRefGoogle Scholar
  21. 21.
    Bischof MG, Bernroider E, Ludwig C, et al. Effect of near physiologic insulin therapy on hypoglycemia counterregulation in type-1 diabetes. Horm Res 2001; 56: 151–8PubMedCrossRefGoogle Scholar
  22. 22.
    Leese GP, Wang J, Broomhall J, et al. Incidence of severe hypoglycaemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabet Med 2002; 19: 12–3CrossRefGoogle Scholar
  23. 23.
    Hardy KJ, Burge MR, Boyle PJ, et al. A treatable cause of recurrent severe hypoglycemia. Diabetes Care 1994 Jul; 17: 722–4PubMedCrossRefGoogle Scholar
  24. 24.
    Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, et al. Prediction of severe hypoglycaemia by angiotensin-converting enzyme activity and genotype in type 1 diabetes. Diabetologia 2003; 46: 89–96PubMedGoogle Scholar
  25. 25.
    Nordfeldt S, Samuelsson U. Serum ACE predicts severe hypoglycemia in children and adolescents with type 1 diabetes. Diabetes Care 2003; 26: 274–8PubMedCrossRefGoogle Scholar
  26. 26.
    Cryer PE. Hypoglycemia begets hypoglycemia in IDDM. Diabetes 1993; 42: 1691–3PubMedGoogle Scholar
  27. 27.
    Cryer PE. Hypoglycemia unawareness in IDDM. Diabetes Care 1993; 3: 40–7Google Scholar
  28. 28.
    Cryer PE. Banting lecture: hypoglycemia: the limiting factor in the management of IDDM. Diabetes 1994; 43: 1378–89PubMedCrossRefGoogle Scholar
  29. 29.
    Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomie failure in insulin dependent diabetes mellitus. J Clin Invest 1993; 91: 819–28PubMedCrossRefGoogle Scholar
  30. 30.
    Rattarasarn C, Dagogo-Jack S, Zachwieja JJ, et al. Hypoglycemia-induced autonomic failure in IDDM is specific for stimulus of hypoglycemia and is not attributable to prior autonomie activation. Diabetes 1994; 43: 809–18PubMedCrossRefGoogle Scholar
  31. 31.
    Cryer PE. Hypoglycemia-associated autonomie failure in insulin-dependent diabetes mellitus. Adv Pharmacol 1998; 42: 620–2PubMedCrossRefGoogle Scholar
  32. 32.
    Cryer PE, Childs BP. Negotiating the barriers of hypoglycemia in diabetes. Diabetes Spectrum 2002; 15: 20–7CrossRefGoogle Scholar
  33. 33.
    Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994; 17: 697–703PubMedCrossRefGoogle Scholar
  34. 34.
    White NH, Skor D, Cryer PE, et al. Identification of type 1 diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med 1983; 308: 485–91PubMedCrossRefGoogle Scholar
  35. 35.
    Towler DA, Havlin CE, Cryer PE. Mechanism of awareness of hypoglycemia: perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 1993; 42: 1791–8PubMedCrossRefGoogle Scholar
  36. 36.
    Schwartz NS, Clutter WE, Shah SD, et al. The glycemic thresholds for activation of glucose counterregulatory systems are higher than the thresholds for symptoms. J Clin Invest 1987; 79: 777–81PubMedCrossRefGoogle Scholar
  37. 37.
    Cryer PE. Hierarchy of physiological responses to hypoglycemia: relevance to clinical hypoglycemia in type I (insulin dependent) diabetes mellitus. Horm Metab Res 1997; 29: 92–6PubMedCrossRefGoogle Scholar
  38. 38.
    Matyka K, Evans M, Lomas J, et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997; 20: 135–41PubMedCrossRefGoogle Scholar
  39. 39.
    Gerich JE, Mokan M, Veneman T, et al. Hypoglycemia unawareness. Endocrine Rev 1991; 12: 356–71CrossRefGoogle Scholar
  40. 40.
    Cryer PE, Fisher JN, Shamoon H. Hypoglycemia. Diabetes Care 1994; 17: 734–55PubMedGoogle Scholar
  41. 41.
    Hepburn DA, Patrick AW, Eadington DW, et al. Unawareness of hypoglycemia in insulin-treated diabetic patients: prevalence and relationship to autonomie neuropathy. Diabet Med 1990; 7: 711–7PubMedCrossRefGoogle Scholar
  42. 42.
    Muhlhauser I, Berger M, Sonnenberg GE, et al. Incidence and management of severe hypoglycemia in 434 patients with insulin-dependent diabetes mellitus. Diabetes Care 1985; 8: 268–73PubMedCrossRefGoogle Scholar
  43. 43.
    MacLeod KM. Hypoglycaemia unawareness: causes, consequences and treatment. J R Coll Physicians Lond 2000; 34: 245–50PubMedGoogle Scholar
  44. 44.
    Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes 1991; 40(2): 223–6PubMedCrossRefGoogle Scholar
  45. 45.
    Ovalle F, Fanelli CG, Paramore DS, et al. Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in type 1 diabetes mellitus. Diabetes 1998; 47: 1472–9PubMedCrossRefGoogle Scholar
  46. 46.
    Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993; 42: 1683–9PubMedCrossRefGoogle Scholar
  47. 47.
    Cranston I, Lomas J, Maran A, et al. Restoration of hypoglycemia unawareness in patients with long duration insulin-dependent diabetes mellitus. Lancet 1994; 344: 283–7PubMedCrossRefGoogle Scholar
  48. 48.
    Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994; 43: 1426–34PubMedCrossRefGoogle Scholar
  49. 49.
    Maggs DG, Jacob R, Rife F, et al. Counterregulation in peripheral tissues: effect of systemic hypoglycemia on levels of substrates and catecholamines in human skeletal muscle and adipose tissue. Diabetes 1997; 46: 70–6PubMedCrossRefGoogle Scholar
  50. 50.
    Amiel SA, Tamborlane WV, Sacca L, et al. Hypoglycemia and glucose counterregulation in normal and insulin-dependent diabetic subjects. Diabetes Metab Rev 1988; 4: 71–89PubMedCrossRefGoogle Scholar
  51. 51.
    McGregor VP, Banarer S, Cryer PE. Elevated endogenous cortisol reduces autonomic neuroendocrine and symptom responses to subsequent hypoglycemia. Am J Physiol Endocrinol Metab 2002; 282: E770–7PubMedGoogle Scholar
  52. 52.
    Gerich JE, Langlois M, Naocco C, et al. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science 1973; 182: 171–3PubMedCrossRefGoogle Scholar
  53. 53.
    Fanelli CG, Pampanelli S, Epifano L, et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycemia following institution of rational intensive therapy in IDDM. Diabetologia 1994; 37: 1265–76PubMedCrossRefGoogle Scholar
  54. 54.
    Simonson DC, Tamborlane WV, DeFronzo RA, et al. Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes. Ann Intern Med 1985; 103: 184–90PubMedGoogle Scholar
  55. 55.
    Ryder RE, Owens DR, Hayes TM, et al. Unawareness of hypoglycaemia and inadequate hypoglycaemic counterregulation: no causal relation with diabetic autonomic neuropathy. BMJ 1990; 301: 783–7PubMedCrossRefGoogle Scholar
  56. 56.
    Hoeldtke RD, Boden G. Epinephrine secretion, hypoglycemia unawareness, and diabetic autonomic neuropathy. Ann Intern Med 1994; 120: 512–7PubMedGoogle Scholar
  57. 57.
    Herold K, Polonsky KS. Does tight glucose control enhance brain sensitivity to low glucose? Diabetes Care 1991; 14: 141–3PubMedGoogle Scholar
  58. 58.
    Boyle PJ, Kempers SF, O’Connor AM, et al. Brain glucose uptake and unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 1726–31PubMedCrossRefGoogle Scholar
  59. 59.
    Boyle PJ, Nagy RJ, O’Connor AM, et al. Adaptation in brain glucose uptake following recurrent hypoglycemia. Proc Natl Acad Sci U S A 1994; 91: 9352–6PubMedCrossRefGoogle Scholar
  60. 60.
    Borg WP, During MJ, Sherwin RS, et al. Ventromedial hypothalamic lesions in rats suppress counterregulatory responses to hypoglycemia. J Clin Invest 1994; 93: 1677–82PubMedCrossRefGoogle Scholar
  61. 61.
    Borg MA, Sherwin RS, Borg WP, et al. Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats. J Clin Invest 1997; 99: 361–5PubMedCrossRefGoogle Scholar
  62. 62.
    Amiel SA, Tamborlane WV, Simonson DC, et al. Defective glucose counterregulation after strict glycemic control of insulin-dependent diabetes mellitus. N Engl J Med 1987; 316: 1376–83PubMedCrossRefGoogle Scholar
  63. 63.
    Powers WJ, Dagogo-Jack S, Markham J, et al. Cerebral transport and metabolism of 1-11C-D-glucose during stepped hypoglycemia. Ann Neurol 1995; 38: 599–609PubMedCrossRefGoogle Scholar
  64. 64.
    Segel SA, Fanelli CG, Dence CS, et al. Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia. Diabetes 2001; 50: 1911–7PubMedCrossRefGoogle Scholar
  65. 65.
    Davis SN, Shavers C, Davis B, et al. Prevention of an increase in plasma cortisol during hypoglycemia preserves subsequent counterregulatory responses. J Clin Invest 1997; 100: 429–38PubMedCrossRefGoogle Scholar
  66. 66.
    Sandoval DA, Ping L, Neill AR, et al. Cortisol acts through central mechanisms to blunt counterregulatory responses to hypoglycemia in conscious rats. Diabetes 2003; 52: 2198–204PubMedCrossRefGoogle Scholar
  67. 67.
    Raju B, McGregor VP, Cryer PE. Cortisol elevations comparable to those that occur during hypoglycemia do not cause hypoglycemia-associated autonomic failure. Diabetes 2003 Aug; 52: 2083–9PubMedCrossRefGoogle Scholar
  68. 68.
    Sherwin RS, Tamborlane WV, Ahern J. Lessons from glucose monitoring at night. Diabetes Care 1987; 10: 249–51PubMedGoogle Scholar
  69. 69.
    Pillar G, Schuscheim G, Weiss R, et al. Interactions between hypoglycemia and sleep architecture in children with type 1 diabetes mellitus. J Pediatr 2003; 142: 163–8PubMedCrossRefGoogle Scholar
  70. 70.
    Perriello G, De Feo P, Torlone E, et al. The dawn phenomenon in type 1 (insulin dependent) diabetes mellitus: magnitude, frequency, variability and dependence on glucose counterregulation and insulin sensitivity. Diabetes 1991; 34: 21–8Google Scholar
  71. 71.
    Jones TW, Porter P, Sherwin RS, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998; 338: 1657–62PubMedCrossRefGoogle Scholar
  72. 72.
    Harsch IA, Stocker S, Radespiel-Troger M, et al. Traffic hypoglycaemias and accidents in patients with diabetes mellitus treated with different antidiabetic regimens. J Intern Med 2002; 252: 352–60PubMedCrossRefGoogle Scholar
  73. 73.
    Ryan CM, Williams TM, Finegold DN, et al. Cognitive dysfunction in adults with type 1 (insulin-dependent) diabetes mellitus of long duration: effects of recurrent hypoglycaemia and other chronic complications. Diabetologia 1993; 36: 329–34PubMedCrossRefGoogle Scholar
  74. 74.
    Perros P, Deary IJ, Sellar RJ, et al. Brain abnormalities demonstrated by magnetic resonance imaging in adult IDDM patients with and without a history of recurrent severe hypoglycemia. Diabetes Care 1997; 20: 1013–8PubMedCrossRefGoogle Scholar
  75. 75.
    Jones TW, McCarthy G, Tamborlane WV, et al. Mild hypoglycemia and impairment of brain stem and cortical evoked potentials in healthy subjects. Diabetes 1990; 39: 1550–5PubMedCrossRefGoogle Scholar
  76. 76.
    Dagogo-Jack S. Diabetes mellitus and related disorders. In: Ahya S, Flood K, Paranjothi S, editors. Washington manual of medical therapeutics. 30th ed. New York: Lippincott, 2001: 455–72Google Scholar
  77. 77.
    Bolli GB. How to ameliorate the problem of hypoglycemia in intensive as well as nonintensive treatment of type 1 diabetes. Diabetes Care 1999; 22Suppl. 2: B43–52PubMedGoogle Scholar
  78. 78.
    American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2003; 26Suppl. 1: S51–61Google Scholar
  79. 79.
    Kalergis M, Schiffrin A, Gougeon R, et al. Impact of bedtime snack composition on prevention of nocturnal hypoglycemia in adults with type 1 diabetes undergoing intensive insulin management using lispro insulin before meals: a randomized, placebo-controlled, crossover trial. Diabetes Care 2003; 26: 9–15PubMedCrossRefGoogle Scholar
  80. 80.
    Gray RO, Butler PC, Beers TR, et al. Comparison of the ability of bread versus bread plus meat to treat and prevent subsequent hypoglycemia in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 1508–11PubMedCrossRefGoogle Scholar
  81. 81.
    Kaufman FR, Halvorsen M, Kaufman ND. A randomized, blinded trial of uncooked cornstarch to diminish nocturnal hypoglycemia at diabetes camp. Diabetes Res Clin Pract 1995; 30: 205–9PubMedCrossRefGoogle Scholar
  82. 82.
    Detlofson I, Kroon M, Aman J. Oral bedtime cornstarch supplementation reduces the risk for nocturnal hypoglycaemia in young children with type 1 diabetes. Acta Paediatr 1999 Jun; 88(6): 595–7PubMedCrossRefGoogle Scholar
  83. 83.
    Ververs MTC, Rouwé C, Smit GPA. Complex carbohydrates in the prevention of nocturnal hypoglycemia in diabetic children. Eur J Clin Nutr 1993; 47: 268–73PubMedGoogle Scholar
  84. 84.
    Matyka KA, Wigg I, Pramming S, et al. Cognitive function and mood after profound nocturnal hypoglycemia in prepubertal children with conventional insulin treatment for diabetes. Arch Dis Child 1999; 81: 138–42PubMedCrossRefGoogle Scholar
  85. 85.
    Holloszy JO, Kohrt WM, Hansen PA. The regulation of carbohydrate and fat metabolism during and after exercise. Front Biosci 1998; 3: D1011–27PubMedGoogle Scholar
  86. 86.
    Chipkin SR, Klugh SA, Chasan-Taber L. Exercise and diabetes. Cardiol Clin 2001; 19: 489–505PubMedCrossRefGoogle Scholar
  87. 87.
    American Diabetes Association. Physical activity/exercise and diabetes mellitus. Diabetes Care 2003; 26Suppl. 1: S73–7Google Scholar
  88. 88.
    McGregor VP, Greiwe JS, Banarer S, et al. Limited impact of vigorous exercise on defenses against hypoglycemia: relevance to hypoglycemia-associated autonomic failure. Diabetes 2002; 51: 1485–92PubMedCrossRefGoogle Scholar
  89. 89.
    Riddell MC, Bar-Or O, Ayub BV, et al. Glucose ingestion matched with total carbohydrate utilization attenuates hypoglycemia during exercise in adolescents with IDDM. Int J Sport Nutr 1999; 9: 24–34PubMedGoogle Scholar
  90. 90.
    Hernandez JM, Moccia T, Fluckey JD, et al. Fluid snacks to help persons with type 1 diabetes avoid late onset postexercise hypoglycemia. Med Sci Sports Exerc 2000; 32: 904–10PubMedGoogle Scholar
  91. 91.
    Wasserman DH, Zinman B. Exercise in individuals with IDDM. Diabetes Care 1994; 17: 924–37PubMedGoogle Scholar
  92. 92.
    Brunelle RL, Llewelyn J, Anderson Jr JH, et al. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998; 21: 1726–31PubMedCrossRefGoogle Scholar
  93. 93.
    Home PD, Lindholm A, Hylleberg B, et al. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998; 21: 1904–9PubMedCrossRefGoogle Scholar
  94. 94.
    Heller SR, Amiel SA, Mansell P. Effect of the fast acting insulin analogue lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy: UK Lispro Study Group. Diabetes Care 1999; 22: 1607–11PubMedCrossRefGoogle Scholar
  95. 95.
    Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes: US Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000; 23: 639–43PubMedCrossRefGoogle Scholar
  96. 96.
    Dagogo-Jack S, Askari H, Morrill B, et al. Physiological responses during hypoglycemia induced by regular human insulin or a novel human analogue, insulin glargine. Diabetes Obes Metab 2000; 2: 373–83PubMedCrossRefGoogle Scholar
  97. 97.
    Yki-Järvinen H, Dressier A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bed time insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes: the HOE 901/3002 Study Group. Diabetes Care 2000; 23: 1130–6PubMedCrossRefGoogle Scholar
  98. 98.
    Vague P, Selam JL, Skeie S, et al. Detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590–6PubMedCrossRefGoogle Scholar
  99. 99.
    Hermansen K, Madsbad S, Perrild H, et al. Comparison of the soluble basal insulin analogue insulin detemir with NPH insulin. Diabetes Care 2001; 24: 296–301PubMedCrossRefGoogle Scholar
  100. 100.
    Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy: an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 2002; 19: 746–51PubMedCrossRefGoogle Scholar
  101. 101.
    Saleh TY, Cryer PE. Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM. Diabetes Care 1997; 20: 1231–6PubMedCrossRefGoogle Scholar
  102. 102.
    Robertson RP. Prevention of recurrent hypoglycemia in type 1 diabetes by pancreas transplantation. Acta Diabetol 1999; 36: 3–9PubMedCrossRefGoogle Scholar
  103. 103.
    Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000 Jul 27; 343: 230–8PubMedCrossRefGoogle Scholar
  104. 104.
    Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50:710–9PubMedCrossRefGoogle Scholar
  105. 105.
    McCrimmon RJ, Sherwin RS. Effect of pancreatic transplantation on counterregulatory hormonal responses to hypoglycaemia. Acta Diabetol 1999; 36: 11–20PubMedCrossRefGoogle Scholar
  106. 106.
    Meyer C, Hering BJ, Grossmann R, et al. Improved glucose counterregulation and autonomic symptoms after intraportal islet transplants alone in patients with long-standing type I diabetes mellitus. Transplantation 1998; 66: 233–40PubMedCrossRefGoogle Scholar
  107. 107.
    Paty BW, Lanz K, Kendall DM, et al. Restored hypoglycemic counterregulation is stable in successful pancreas transplant recipients for up to 19 years after transplantation. Transplantation 2001; 72: 1103–7PubMedCrossRefGoogle Scholar
  108. 108.
    Bolli GB, De Feo P, De Cosmo S, et al. A reliable and reproducible test for adequate glucose counterregulation in type 1 diabetes. Diabetes 1984; 33: 732–7PubMedCrossRefGoogle Scholar
  109. 109.
    Fritsche A, Stumvoll M, Haring HU, et al. Reversal of hypoglycemia unawareness in a long-term type 1 diabetic patient by improvement of beta-adrenergic sensitivity after prevention of hypoglycemia. J Clin Endocrinol Metab 2000; 85: 523–5PubMedCrossRefGoogle Scholar
  110. 110.
    Lingenfelser T, Buettner UW, Uhl H, et al. Recovery of hypoglycaemia-associated compromised cerebral function after a short interval of euglycaemia in insulin-dependent diabetic patients. Electroencephalogr Clin Neurophysiol 1994; 92: 196–203PubMedCrossRefGoogle Scholar
  111. 111.
    Dagogo-Jack S, Fanelli CG, Cryer PE. Durable reversal of hypoglycemia unawareness in type 1 diabetes. Diabetes Care 1999; 22: 866–7PubMedCrossRefGoogle Scholar
  112. 112.
    Debrah K, Sherwin RS, Murphy J, et al. Effect of caffeine on recognition of and physiological responses to hypoglycaemia in insulin-dependent diabetes. Lancet 1996; 347: 19–24PubMedCrossRefGoogle Scholar
  113. 113.
    Watson JM, Jenkins EJ, Hamilton P, et al. Influence of caffeine on the frequency and perception of hypoglycemia in free-living patients with type 1 diabetes. Diabetes Care 2000; 23: 455–9PubMedCrossRefGoogle Scholar
  114. 114.
    de Galan BE, Tack CJ, Lenders JW, et al. Theophylline improves hypoglycemia unawareness in type 1 diabetes. Diabetes 2002; 51: 790–6PubMedCrossRefGoogle Scholar
  115. 115.
    Kinsley BT, Weinger K, Bajaj M, et al. Blood glucose awareness training and epinephrine responses to hypoglycemia during intensive treatment in type 1 diabetes. Diabetes Care 1999; 22: 1022–8PubMedCrossRefGoogle Scholar
  116. 116.
    Clarke WL, Cox DJ, Gonder-Frederick L, et al. Biopsychobehavioral model of risk of severe hypoglycemia: self-management behaviors. Diabetes Care 1999; 22: 580–4PubMedCrossRefGoogle Scholar
  117. 117.
    Fritsche A, Stumvoll M, Renn W, et al. Diabetes teaching program improves glycemic control and preserves perception of hypoglycemia. Diabetes Res Clin Pract 1998; 40: 129–35PubMedCrossRefGoogle Scholar
  118. 118.
    Cox DJ, Gonder-Frederick L, Polonsky W, et al. Blood glucose awareness training (BGAT-2): long-term benefits. Diabetes Care 2001; 24: 637–42PubMedCrossRefGoogle Scholar
  119. 119.
    Wiethop BV, Cryer PE. Alanine and terbutaline in the treatment of hypoglycemia in IDDM. Diabetes Care 1993; 16: 1131–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Department of Medicine (Endocrinology) & General Clinical Research CenterUniversity of Tennessee Health Science CenterMemphisUSA
  2. 2.University of Tennessee College of MedicineMemphisUSA

Personalised recommendations